Ivacaftor Safe in Cystic Fibrosis With Non-G551D Gating Mutations
Ivacaftor is safe and effective in patients with cystic fibrosis who have severe lung disease and non-G551D gating mutations.
All articles by Virginia Schad, PharmD
Azathioprine and Mycophenolate Mofetil May Benefit Myositis-Related ILD
In patients with myositis-related interstitial lung disease, azathioprine and mycophenolate mofetil treatment offers clinical improvements and a reduction in prednisone dose.
Adaptive vs Pressure Support in Noninvasive Ventilation in COPD Acute Exacerbations
According to the results of an exploratory study, adaptive support ventilation mode performed as well as pressure support ventilation in patients with acute exacerbations of COPD.
Obstructive Sleep Apnea Heritable but Daytime Sleepiness Influenced by Environment
Obstructive sleep apnea and the indices of severity are heritable, while daytime sleepiness is mostly influenced by environmental factors.
Novel Topical Steroid Delivery System Shows Efficacy in Nasal Polyps
The fluticasone exhalation delivery system is a novel topical steroid delivery system that is an important adjunct therapy for sinonasal inflammatory disease.
Higher vs Standard Dose Steroid After Endoscopic Sinus Surgery for Nasal Polyposis
There is no significant increased benefit in using a higher-dose nasal steroid spray compared with the standard dose after endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyposis.
Biologic Therapies May Reduce Asthma Exacerbation and Modestly Improve Quality of Life
The Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council found all 5 FDA-approved biologic therapies to reduce asthma exacerbation, but the cost-effectiveness does not match the effectiveness of the therapies.
Clinical Features of Three Rare Diseases Associated With Bronchiectasis
Severe alpha-1 antitrypsin deficiency, common variable immunodeficiency, and primary ciliary dyskinesia are all associated with bronchiectasis.
High-Dose Aspirin Increases Type 2 Inflammation in AERD
High-dose aspirin therapy paradoxically increases markers of type 2 inflammation in patients with aspirin-exacerbated respiratory disease despite reducing nasal symptoms.
Weight Loss Improves Asthma Control and Quality of Life
Researchers found data to support weight loss for patients who are obese and have asthma.
Next post in Asthma Advisor Channel
